Highest development stage: Phase 1

Development status: Inactive

Gram-positive activity

Gram-negative activity

Combination therapy: No antimicrobial activity (2) so would need to have been paired with a β-lactam

Mechanism of Action/Target pathogen: Triazolyl methylene penem that is a potent inhibitor of TEM and SHV type plasmid β-lactamases and also chromosomal Cephalosporinases of Enterobacter and Citrobacter. In combination with amoxycillin alowed activity against resistant (β-lactamase producing) bacteria such as Xanthamonas maltophilia, B. fragilis and more

Reason dropped: No antimicrobial activity (2)-by 2004 it was no longer in clinical development but may well have been discontinued earlier. Whilst it is a very potent inhibitor, it is quickly eliminated with an extrapolated terminal t½ of 31mins (1). BRL 42715, its development has been discontinued as a result of its low serum half-life (2)